Vascular Solutions
CT and MRI-based vascular and cardiac biomarkers for cardiovascular conditions
Software · Cloud SaaSCompany source
Company profile
About VIDA Diagnostics
VIDA Diagnostics is a clinical imaging intelligence company that accelerates the approval and adoption of lifesaving therapies through AI-powered digital biomarker solutions. The company empowers life sciences organizations to collect high-quality imaging data and harness artificial intelligence to accelerate drug development and approval processes. VIDA's services are enabled by the VIDA Intelligence Platform, an AI-powered cloud system that streamlines imaging in clinical trials and facilitates reliable imaging data from over 1,500 certified sites around the globe. The company's foundation is in quantitative imaging for respiratory diseases including COPD, asthma, ILD/IPF, cystic fibrosis, and COVID-19, producing up to 15,000 individual metrics from a single imaging scan across 50+ biomarkers. VIDA has expanded its capabilities to include cardiovascular and oncology biomarkers, as well as neurology, musculoskeletal, and gastroenterology applications. The platform provides comprehensive clinical trial imaging services including AI-powered digital biomarkers, site management, radiology assessments, and sponsor trial orchestration. VIDA serves pharmaceutical innovators by building digital biobanks—repositories of digital patient information over time including imaging data, test results, demographics, and diagnoses. With over 20 years of experience, the company has processed 500,000+ imaging scans across 30+ active trials in 40+ countries, working with 5 of the top 10 global pharmaceutical companies. The company's proprietary imaging biomarkers enable precise quantitative endpoints and help biopharma sponsors save millions in drug development costs through improved patient targeting, external control arms, and digital twin capabilities.
Company description VIDA Diagnostics official website
Primary marketMedical Imaging & Radiology
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at VIDA Diagnostics?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Asthma
- COPD
- Coronary Artery Disease
- Coronary Heart Disease
- COVID-19
- Cystic Fibrosis
- Gastroenterology conditions
- ILD/IPF
- Musculoskeletal conditions
- Neurological conditions
- Pulmonary Arterial Hypertension
- Pulmonary Embolism
- Right Ventricular Dysfunction
- Solid tumors
Who it serves
- Biotechnology companies
- Clinical research organizations
- Life sciences companies
- Pharmaceutical companies
Deployment & integration
Cloud Saas deployment with recorded integration context.
Geographic context
MarketsEurope · Global - 40+ countries · United States
Company sourceOfficial website
Company milestones
Platform expansion
Expanded from respiratory-only to cardiovascular and oncology biomarkers, integrated partnerships with Polarean, Thirona, and Riverain for enhanced imaging capabilities, built digital biobank with 1B+ biological metrics and 500TB+ multi-omic data from 500k+ patients
Partnerships
Recorded partners
- Polarean (Xenon MRI)
- Riverain (ClearRead CT technology)
- Thirona (AI-powered thoracic imaging analysis)
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
Clinical Trial Imaging Services
Platform-enabled services for exceptional imaging data quality and efficient site operations
Service · Cloud SaaSCompany source
Digital Biobank
Repository of digital patient information including imaging data, test results, and demographics
Platform · Cloud SaaSCompany source
External Control Arms
Reduce trial size by creating control arms from the digital biobank
Service · Cloud SaaSCompany source
Oncology Imaging Biomarkers
Tumor response measures including RECIST 1.1 and advanced tumor analysis
Software · Cloud SaaSCompany source
Respiratory Imaging Biomarkers
Quantitative imaging for all major respiratory diseases including COPD, asthma, ILD/IPF, and more
Software · Cloud SaaSCompany source
VIDA Intelligence Platform
AI-powered clinical trial imaging platform for high-quality imaging data collection and analysis
Platform · Cloud SaaSCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Classifying chronic obstructive pulmonary disease status using computed tomography imaging and convolutional neural networks: comparison of model input image types and training data severity.Journal of medical imaging (Bellingham, Wash.) · May 1, 2025
CT strain metrics allow for earlier diagnosis of bronchiolitis obliterans syndrome after hematopoietic cell transplant.Blood advances · Oct 8, 2024
A Novel Air Trapping Segment Score Identifies Opposing Effects of Obesity and Eosinophilia on Air Trapping in Asthma.American journal of respiratory and critical care medicine · May 15, 2024
Use of Quantitative CT Imaging to Identify Bronchial Thermoplasty Responders.Chest · Apr 1, 2024
Tezepelumab and Mucus Plugs in Patients with Moderate-to-Severe Asthma.NEJM evidence · Oct 1, 2023
Quantitative CT Evaluation of Small Pulmonary Vessels Has Functional and Prognostic Value in Pulmonary Hypertension.Radiology · Nov 1, 2022
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
VIDAvisionK200990 · 510k · Aug 7, 2020
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
15,000 individual metrics from single scan
Quantitative biomarker extraction capability
50+ biomarkers
Measuring airway, tissue, vascular remodel, and lung function
Millions in cost savings
Drug development cost reduction for biopharma sponsors
700% growth
Utilization of imaging biomarkers in clinical trials
5 of Top 10 Global Pharma Companies
Clinical trial imaging and AI-powered digital biomarker analysis
500,000+ imaging scans processed across 30+ active trials with 1,500+ certified clinical trial sites
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
Susan Wood
CEO
Lars Nordenmark
Chief Scientific Officer
Sandra Stapleton
COO
Todd Johnson
CTO
Joe Reif
Vice President of Clinical and Business Development
John Newell
Medical Director
Margaret Cranston
Vice President, Commercial Operations
Michael Blaha
VP, Engineering & Development
06 · Company updates
Updates from VIDA Diagnostics
Recent articles published on VIDA Diagnostics's official website.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Medical Imaging & Radiology
Companies that apply AI to analyze medical images for diagnostic purposes, workflow optimization, or clinical decision support. Covers general radiology (X-rays, CT scans, MRIs, ultrasounds) across multiple organ systems, as well as specialized imaging in ophthalmology and dermatology.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.